Investigational New Drugs

, Volume 25, Issue 5, pp 411–416 | Cite as

Modulation of tumor radiation response with G3139, a bcl-2 antisense oligonucleotide

  • Nicole Wiedenmann
  • Masashi Koto
  • Uma Raju
  • Luka Milas
  • Kathryn A. Mason


Overexpression of anti-apoptotic bcl-2 protein has been found in hematological and solid tumors and has been associated with increased resistance against cytotoxic therapy. While bcl-2 antisense (AS) treatment combined with chemotherapy has been successfully tested in clinical trials, trials evaluating the combination of bcl-2 AS with radiotherapy have not yet been performed. The aim of this study was to investigate in vivo anti-tumor effects of a combined modality treatment scheme consisting of radiation and the bcl-2 targeted AS oligonucleotide (ODN) G3139 (Oblimersen Sodium). Two human colon carcinoma cell lines, SW620, bcl-2 positive and HT-29, bcl-2 negative, were grown as xenografts and compared in their response to combined bcl-2 AS/radiation treatment. G3139 potentiated the radiation response of bcl-2 positive SW620 tumors, but had no significant effect on bcl-2 negative HT-29 tumors assayed by tumor growth delay. The profound enhancement of SW620 tumor growth delay by G3139 did not translate into effects on tumor cure, as no significant effect of G3139 was found on SW620 radiocurability (TCD50 assay). The control ODN G3622 had no effect on SW620 radiation response, indicating an ODN sequence specific effect.


Bcl-2 Colon cancer Antisense oligonucleotide Xenografts Radiation response TCD50 Tumor growth delay 



This work was supported by National Cancer Institute Cancer Center Core Grants CA-16632 and CA-06294, and by a Laboratory Study Agreement with Aventis. The expert technical assistance of Robert Neal, David Valdecanas, Nancy Hunter, and Jessica Pickett are gratefully acknowledged.


  1. 1.
    Klasa RJ, Gillum AM, Klem RE, Frankel SR (2002) Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment. Antisense Nucleic Acid Drug Dev 12:193–213PubMedCrossRefGoogle Scholar
  2. 2.
    Zhao DP, Ding XW, Peng JP, Zheng YX, Zhang SZ (2005) Prognostic significance of bcl-2 and p53 expression in colorectal carcinoma. J Zhejiang Univ Sci B 6:1163–1169PubMedCrossRefGoogle Scholar
  3. 3.
    De Cesare M, Perego P, Righetti SC, Pratesi G, Carenini N, Rivoltini L, Zupi G, Del Bufalo D, Balsari A, Zunino F (2005) Enhanced antitumour efficacy of gimatecan in combination with Bcl-2 antisense oligonucleotide in human melanoma xenografts. Eur J Cancer 41:1213–1222PubMedCrossRefGoogle Scholar
  4. 4.
    Kim R, Emi M, Tanabe K, Toge T (2004) Preclinical evaluation of antisense bcl-2 as a chemosensitizer for patients with gastric carcinoma. Cancer 101:2177–2186PubMedCrossRefGoogle Scholar
  5. 5.
    Lopes de Menezes DE, Hudon N, McIntosh N, Mayer LD (2000) Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin. Clin Cancer Res 6:2891–2902PubMedGoogle Scholar
  6. 6.
    Mita MM, Ochoa L, Rowinsky EK, Kuhn J, Schwartz G, Hammond LA, Patnaik A, Yeh IT, Izbicka E, Berg K, Tolcher AW (2006) A phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (Genasense, G3139) and irinotecan in patients with metastatic colorectal cancer. Ann Oncol 17:313–321PubMedCrossRefGoogle Scholar
  7. 7.
    Tolcher AW, Chi K, Kuhn J, Gleave M, Patnaik A, Takimoto C, Schwartz G, Thompson I, Berg K, D’Aloisio S, Murray N, Frankel SR, Izbicka E, Rowinsky E (2005) A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer. Clin Cancer Res 11:3854–3861PubMedCrossRefGoogle Scholar
  8. 8.
    Tolcher AW, Kuhn J, Schwartz G, Patnaik A, Hammond LA, Thompson I, Fingert H, Bushnell D, Malik S, Kreisberg J, Izbicka E, Smetzer L, Rowinsky EK (2004) A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer. Clin Cancer Res 10:5048–5057PubMedCrossRefGoogle Scholar
  9. 9.
    Winegarden JD, Mauer AM, Otterson GA, Rudin CM, Villalona-Calero MA, Lanzotti VJ, Szeto L, Kasza K, Hoffman PC, and Vokes EE (2004) A phase II study of oxaliplatin and paclitaxel in patients with advanced non-small-cell lung cancer. Ann Oncol 15:915–920PubMedCrossRefGoogle Scholar
  10. 10.
    Morris MJ, Tong WP, Cordon-Cardo C, Drobnjak M, Kelly WK, Slovin SF, Terry KL, Siedlecki K, Swanson P, Rafi M, DiPaola RS, Rosen N, Scher HI (2002) Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer. Clin Cancer Res 8:679–683PubMedGoogle Scholar
  11. 11.
    Bedikian AY, Millward M, Pehamberger H, Conry R, Gore M, Trefzer U, Pavlick AC, DeConti R, Hersh EM, Hersey P, Kirkwood JM, and Haluska FG (2006) Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 24:4738–4745PubMedCrossRefGoogle Scholar
  12. 12.
    Mu Z, Hachem P, Pollack A (2005) Antisense Bcl-2 sensitizes prostate cancer cells to radiation. Prostate 65:331–340PubMedCrossRefGoogle Scholar
  13. 13.
    O’Brien S, Moore JO, Boyd TE, Larratt LM, Skotnicki A, Koziner B, Chanan-Khan AA, Seymour JF, Bociek RG, Pavletic S, Rai KR (2007) First Antisense Drug Provides Benefit to Subset of Chronic Lymphocytic Leukemia Patients. J Clin Oncol. 25 10.1200/JCO.2006.07.1191 (Early release)Google Scholar
  14. 14.
    Yip KW, Mocanu JD, Au PY, Sleep GT, Huang D, Busson P, Yeh WC, Gilbert R, O’Sullivan B, Gullane P, Bastianutto C, Liu FF (2005) Combination bcl-2 antisense and radiation therapy for nasopharyngeal cancer. Clin Cancer Res 11:8131–8144PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Nicole Wiedenmann
    • 1
    • 2
  • Masashi Koto
    • 1
  • Uma Raju
    • 1
  • Luka Milas
    • 1
  • Kathryn A. Mason
    • 1
  1. 1.Department of Experimental Radiation OncologyThe University of Texas M. D. Anderson Cancer CenterHoustonUSA
  2. 2.Department of Radiation Oncology, Klinikum rechts der IsarTechnical University of MunichMunichGermany

Personalised recommendations